ClinicalTrials.gg
Active, not recruitingNCT06001151ACHELOUSUpdated Oct 16, 2026

Cadonilimab (AK104) Plus Chemotherapy as First-line Treatment in Non-squamous Non-Small Cell Lung Cancer (NSCLC) Patients With Programmed Cell Death Ligand 1 (PD-L1) Negative

A Phase 2 interventional study of Cadonilimab and Pemetrexed in Carcinoma, Non-Small-Cell Lung, sponsored by Qian Chu. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Qian Chu · Phase 2, Interventional, and Treatment

How we know

Updated Oct 16, 2026Now Active, not recruitingGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
49
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies testing cadonilimab in Carcinoma, Non-Small-Cell Lung — 10 open to participants now, 13 under way, 2 of them phase 3. cadonilimab · Carcinoma, Non-Small-Cell Lung.

Planned enrollment
6th of 15
49 · median 44
Started
2023
with 7 others
Phase 2
11 of 15
8 open now
Primary completion
2025-08
later than 5 of 12 live
Registered
8th of 15
by date
Lead sponsor
1 of 15
Qian Chu

Among the 15 studies testing cadonilimab in Carcinoma, Non-Small-Cell Lung, this one is the 6th largest by planned enrollment, is one of 8 that started in 2023, is one of 11 in phase 2, reaches primary completion later than 5 of the 12 other live ones, and was the 8th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

10 of the 15 studies testing cadonilimab in Carcinoma, Non-Small-Cell Lung are open now, in 1 country. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

About cadonilimab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing cadonilimab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This is a single arm, multi-center clinical trial. Target population is advanced or metastatic non-squamous Non-Small Cell Lung Cancer (NSCLC) Patients with Programmed Cell Death Ligand 1 (PD-L1) negative, aiming to evaluate the efficacy and safety of the combination therapy of Cadonilimab and chemotherapy. Cadonilimab is a PD-1/CTLA-4 bi-specific antibody.

Read the detailed description

This trial enrolled advanced or metastatic non-squamous Non-Small Cell Lung Cancer (NSCLC) Patients with Programmed Cell Death Ligand 1 (PD-L1) negative. Patients will receive cadonilimab (10mg/kg) plus pemetrexed(500mg/m2) and carboplatin (AUC=5) every 3 weeks for 4 cycles, follwed with cadonilimab (10mg/kg) plus pemetrexed (500mg/m2) every 3 weeks as maintenance therapy. The primary endpoint is 12-month progression-free-survival (PFS) rate assessed by investigators. Key secondary endpoints include objective response rate (ORR), duration of response (DOR), disease control rate (DCR), time to response (TTR), progression free survival (PFS), overall survival (OS), and safety.

03

Conditions studied

  • Carcinoma, Non-Small-Cell Lung

Keywords

  • non-squamous Non-Small Cell Lung Cancer
  • Programmed Cell Death Ligand 1
  • cadonilimab
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with histologically/cytologically stage IIIB, IIIC, IV non-squamous Non-Small Cell Lung Cancer (NSCLC)
  • TPS\<1%
  • more than 3 months
  • Without EGFR-sensitive mutation (19Exon del/21Exon L858R), ALK, ROS1 gene rearrangement or fusion
  • Has no prior systemic therapy; (chemotherapy and/or radiotherapy is allowed as part of /adjuvant therapy. Patients who have had recurrence or for more than 6 months from the end of neoadjuvant/adjuvant treatment would be enrolled)
  • score 0-1
  • Patients must have at least one according to 1.1
  • Has adequate organ function
  • Agree to provide tumour tissue samples for biomarker exploration (including but not limited to PD-L1 IHC or NGS testing)
  • Voluntarily sign a written form

Exclusion criteria

Exclusion Criteria:

  • Histological examination with Small Cell Lung Cancer or squamous Non-Small Cell Lung Cancer
  • With active central nervous system (CNS) confirmed by CT or MRI
  • With other within 3 years before enrollment
  • With severe infections within 4 weeks of the first dose of study treatment
  • Women who are pregnant or lactating
  • History of interstitial lung disease, drug-induced interstitial lung disease, or radiation pneumonia requiring hormone therapy
  • History of myocarditis, cardiomyopathy, and malignant arrhythmia
  • Tumor compresses important surrounding organs (such as the esophagus) with accompanying symptoms, compressing the superior vena cava or invading the mediastinal vessels, heart, etc.
  • Risk of bleeding, major hemoptysis, or with history of coagulation dysfunction
  • Active diseases that require systematic treatment within 2 years before enrollment
  • History of (HIV)
  • With active infection
  • With uncontrollable pleural effusion, pericardial effusion, or ascites that require repeated drainage
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
49 participants (estimated)

Study arms

  • Experimental
    Experimental Arm

    Patients will receive cadonilimab (10mg/kg) plus pemetrexed(500mg/m2) and carboplatin (AUC=5) every 3 weeks for 4 cycles, follwed with cadonilimab (10mg/kg) plus pemetrexed (500mg/m2) every 3 weeks as maintenance therapy.

    Drug: Cadonilimab · Drug: Pemetrexed · Drug: Carboplatin

Interventions

  • Patients receive cadonilimab (10mg/kg) every 3 weeks.

    Also known as: AK104

  • Patients receive pemetrexed (500mg/m2) every 3 weeks.

  • Patients receive carboplatin (AUC=5) every 3 weeks for 4 cycles.

06

What researchers measure

Primary outcomes

  1. 12-month progression-free-survival (PFS) rate

    Rate of patients with complete/partial response at 12-month from enrollment

    Time frame: At 12 months

Secondary outcomes

  1. objective response rate (ORR)

    objective response rate using RECIST 1.1 criteria

    Time frame: about 24 months

  2. duration of response (DOR)

    Time from the date of the first documented response (CR or PR) to the earliest date of disease progression (RECIST 1.1), or death due to any cause

    Time frame: about 24 months

  3. disease control rate (DCR)

    disease control rate using RECIST 1.1 criteria

    Time frame: about 24 months

  4. time to response (TTR)

    Time from the date of enrollment to the first documented response (CR or PR) (RECIST 1.1)

    Time frame: about 24 months

  5. progression free survival (PFS)

    Time from enrollment to first observation of progression (RECIST1.1) or date of death (from any cause)

    Time frame: about 24 months

  6. overall survival (OS)

    Time from enrollment until death due to any cause

    Time frame: about 24 months

  7. incidence, type and severity of adverse events

    Descriptive statistics of safety will be presented using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 5.0

    Time frame: From time of informed consent through treatment period and up to 30 days post last dose of study treatment (about 24 months)

07

Study locations

1 site
  • Qian Chu
    Wuhan, Hubei 430030, China
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2023 to primary completion in Aug 2025, 24 months.

Of 732 non-industry phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 84. This study's 24 months is below that.

Counting every sponsor, half of 1,049 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2023
First posted
Aug 21, 2023
StartActual
Aug 7, 2023
Primary completionActual
Aug 31, 2025
CompletionEst.
Aug 31, 2027
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Recruiting→Active, not recruiting
    + 6 other changes: index terms, verification date, date precision, oversight details, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06001151
Lead sponsor
Qian Chu
Collaborators
Akeso Pharmaceuticals, Inc.
Responsible party
Qian Chu (Professor, Tongji Hospital) — Sponsor-investigator
First posted
Aug 21, 2023
Start date
Aug 7, 2023
Primary completion
Aug 31, 2025
Completion
Aug 31, 2027 (estimated)
Last update
Oct 16, 2026

Study contacts

Qian Chu
principal investigator · Tongji Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cadonilimab

Start the discussion